首页> 外文期刊>Brachytherapy >Palladium-103 eye plaque brachytherapy for primary adenocarcinoma of the ciliary body epithelium
【24h】

Palladium-103 eye plaque brachytherapy for primary adenocarcinoma of the ciliary body epithelium

机译:钯103眼斑斑近距离放射疗法治疗原发性睫状上皮腺癌

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To present an interventional case report on the use of plaque brachytherapy for adenocarcinoma of the nonpigmented ciliary epithelium. Methods and materials: A 36-year-old woman with unilateral right eye pain and finger counting vision was noted to have an anterior segment intraocular mass. It extended between the iris and lens and into the pupillary aperture. High-frequency ultrasound imaging revealed a ciliary body origin. A minimally invasive biopsy technique allowed for a cytology and histopathology diagnosis of primary adenocarcinoma of the ciliary epithelium. Treatment was performed with palladium-103 ophthalmic plaque brachytherapy (80-Gy apex). Main outcome measures include visual acuity, local control, radiation complications, and metastatic disease. Results: The patient presented with counting fingers vision, focal angle closure, cataract, and a 5.5-mm thick ciliary body malignancy. At 3 years after radiation therapy and 2.5 years after cataract extraction, her visual acuity was improved to 20/30 and the tumor residua stabilized at 60% of its initial thickness. There has been neither radiation-related keratopathy, retinopathy, optic neuropathy nor metastatic disease. Conclusions: Plaque brachytherapy was used to treat primary adenocarcinoma of the ciliary epithelium. With 3-year followup, there has been excellent local control, preservation of the eye, and recovery of vision.
机译:目的:提出有关斑块近距离放射疗法治疗非色素性睫状上皮腺癌的介入性病例报告。方法和材料:注意到一名36岁的女性,患有单侧右眼疼痛和手指计数视力,存在眼前段眼内肿块。它在虹膜和晶状体之间延伸并进入瞳孔。高频超声成像显示睫状体起源。微创活检技术可对原发性睫状上皮腺癌进行细胞学检查和组织病理学诊断。用钯103眼科斑块近距离放射治疗(80-Gy顶点)进行治疗。主要结果指标包括视力,局部控制,放射并发症和转移性疾病。结果:该患者出现手指视觉计数,焦距闭合,白内障和5.5毫米厚的睫状体恶性肿瘤。放疗后3年和白内障摘除后2.5年,她的视力提高到20/30,肿瘤残留物稳定在其初始厚度的60%。既没有与辐射有关的角膜病变,视网膜病变,视神经病变也没有转移性疾病。结论:斑块近距离放射治疗被用于治疗原发性睫状上皮腺癌。经过3年的随访,可以实现出色的局部控制,保护眼睛和恢复视力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号